Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.

Itamochi H, Kato M, Nishimura M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2012 Dec;25(4):111-5. doi: 10.1007/s13577-012-0048-1. Epub 2012 Dec 30.

PMID:
23274876
2.

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Itamochi H, Kato M, Nishimura M, Oumi N, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2013 Sep;26(3):121-7. doi: 10.1007/s13577-013-0062-y. Epub 2013 Feb 21.

PMID:
23430509
3.

Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Sato S, Itamochi H, Oumi N, Chiba Y, Oishi T, Shimada M, Sato S, Chikumi J, Nonaka M, Kudoh A, Komatsu H, Harada T, Sugiyama T.

Hum Cell. 2016 Oct;29(4):181-7. doi: 10.1007/s13577-016-0138-6. Epub 2016 Mar 9.

PMID:
26960408
4.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

5.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.

Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650.

6.

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.

7.

Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, Riccardi R.

Neuro Oncol. 2009 Jun;11(3):250-9. doi: 10.1215/15228517-2008-095. Epub 2008 Nov 25.

8.

Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.

Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, Sato S, Nonaka M, Terakawa N, Kigawa J, Harada T.

Clin Cancer Res. 2011 Jul 15;17(14):4742-50. doi: 10.1158/1078-0432.CCR-11-0190. Epub 2011 May 24.

9.

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.

Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7.

10.

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.

J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103. doi: 10.1093/jnci/djn216. Epub 2008 Jul 29.

11.
12.

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M.

Clin Cancer Res. 2011 Dec 15;17(24):7816-27. doi: 10.1158/1078-0432.CCR-11-0408. Epub 2011 Oct 20.

13.

Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.

Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.

Cancer Lett. 2015 Jan 28;356(2 Pt B):862-71. doi: 10.1016/j.canlet.2014.10.040. Epub 2014 Nov 4.

PMID:
25449780
14.

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.

Clin Cancer Res. 2010 Mar 1;16(5):1509-19. doi: 10.1158/1078-0432.CCR-09-1112. Epub 2010 Feb 23.

15.

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M.

J Exp Clin Cancer Res. 2014 May 30;33:47. doi: 10.1186/1756-9966-33-47.

16.
17.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

18.

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.

Guo XF, Zhu XF, Zhong GS, Deng BG.

Dis Esophagus. 2013 Jul;26(5):487-95. doi: 10.1111/j.1442-2050.2012.01332.x. Epub 2012 Mar 27. Retraction in: Dis Esophagus. 2014 Nov-Dec;27(8):802.

PMID:
22458639
19.

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.

Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.

20.

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J.

PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487. Epub 2011 Jul 18.

Supplemental Content

Support Center